Literature DB >> 30591591

PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.

Kevin H Kensler1,2, Venkat N Sankar3, Jun Wang4,5, Xuehong Zhang1, Christopher A Rubadue3, Gabrielle M Baker3, Joel S Parker6, Katherine A Hoadley6, Andreea L Stancu3, Michael E Pyle3, Laura C Collins3, David J Hunter1,2,7, A Heather Eliassen1,2, Susan E Hankinson1,2,5, Rulla M Tamimi1,2, Yujing J Heng8,9.   

Abstract

BACKGROUND: Modified median and subgroup-specific gene centering are two essential preprocessing methods to assign breast cancer molecular subtypes by PAM50. We evaluated the PAM50 subtypes derived from both methods in a subset of Nurses' Health Study (NHS) and NHSII participants; correlated tumor subtypes by PAM50 with IHC surrogates; and characterized the PAM50 subtype distribution, proliferation scores, and risk of relapse with proliferation and tumor size weighted (ROR-PT) scores in the NHS/NHSII.
METHODS: PAM50 subtypes, proliferation scores, and ROR-PT scores were calculated for 882 invasive breast tumors and 695 histologically normal tumor-adjacent tissues. Cox proportional hazards models evaluated the relationship between PAM50 subtypes or ROR-PT scores/groups with recurrence-free survival (RFS) or distant RFS.
RESULTS: PAM50 subtypes were highly comparable between the two methods. The agreement between tumor subtypes by PAM50 and IHC surrogates improved to fair when Luminal subtypes were grouped together. Using the modified median method, our study consisted of 46% Luminal A, 18% Luminal B, 14% HER2-enriched, 15% Basal-like, and 8% Normal-like subtypes; 53% of tumor-adjacent tissues were Normal-like. Women with the Basal-like subtype had a higher rate of relapse within 5 years. HER2-enriched subtypes had poorer outcomes prior to 1999.
CONCLUSIONS: Either preprocessing method may be utilized to derive PAM50 subtypes for future studies. The majority of NHS/NHSII tumor and tumor-adjacent tissues were classified as Luminal A and Normal-like, respectively. IMPACT: Preprocessing methods are important for the accurate assignment of PAM50 subtypes. These data provide evidence that either preprocessing method can be used in epidemiologic studies. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30591591      PMCID: PMC6449178          DOI: 10.1158/1055-9965.EPI-18-0863

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  42 in total

1.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

Review 2.  Established breast cancer risk factors and risk of intrinsic tumor subtypes.

Authors:  Mollie E Barnard; Caroline E Boeke; Rulla M Tamimi
Journal:  Biochim Biophys Acta       Date:  2015-06-10

3.  A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Authors:  Torsten O Nielsen; Joel S Parker; Samuel Leung; David Voduc; Mark Ebbert; Tammi Vickery; Sherri R Davies; Jacqueline Snider; Inge J Stijleman; Jerry Reed; Maggie C U Cheang; Elaine R Mardis; Charles M Perou; Philip S Bernard; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2010-09-13       Impact factor: 12.531

4.  Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies.

Authors:  Julia S Sisti; Laura C Collins; Andrew H Beck; Rulla M Tamimi; Bernard A Rosner; A Heather Eliassen
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

5.  Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Authors:  Patricia Casbas-Hernandez; Xuezheng Sun; Erick Roman-Perez; Monica D'Arcy; Rupninder Sandhu; Asahi Hishida; Kirk K McNaughton; Xiaohong R Yang; Liza Makowski; Mark E Sherman; Jonine D Figueroa; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-02       Impact factor: 4.254

6.  Challenges in projecting clustering results across gene expression-profiling datasets.

Authors:  Lara Lusa; Lisa M McShane; James F Reid; Loris De Cecco; Federico Ambrogi; Elia Biganzoli; Manuela Gariboldi; Marco A Pierotti
Journal:  J Natl Cancer Inst       Date:  2007-11-13       Impact factor: 13.506

7.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Authors:  Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker
Journal:  BMC Med Genomics       Date:  2015-08-22       Impact factor: 3.063

8.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Authors:  Rulla M Tamimi; Heather J Baer; Jonathan Marotti; Mark Galan; Laurie Galaburda; Yineng Fu; Anne C Deitz; James L Connolly; Stuart J Schnitt; Graham A Colditz; Laura C Collins
Journal:  Breast Cancer Res       Date:  2008-08-05       Impact factor: 6.466

9.  Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival--Evidence from TCGA Pan-Cancer Data.

Authors:  Xiu Huang; David F Stern; Hongyu Zhao
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

10.  DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas.

Authors:  Melissa A Troester; Katherine A Hoadley; Monica D'Arcy; Andrew D Cherniack; Chip Stewart; Daniel C Koboldt; A Gordon Robertson; Swapna Mahurkar; Hui Shen; Matthew D Wilkerson; Rupninder Sandhu; Nicole B Johnson; Kimberly H Allison; Andrew H Beck; Christina Yau; Jay Bowen; Margi Sheth; E Shelley Hwang; Charles M Perou; Peter W Laird; Li Ding; Christopher C Benz
Journal:  NPJ Breast Cancer       Date:  2016-05-04
View more
  10 in total

1.  Involvement of fine particulate matter exposure with gene expression pathways in breast tumor and adjacent-normal breast tissue.

Authors:  Natalie C DuPré; Yujing J Heng; Benjamin A Raby; Kimberly Glass; Jaime E Hart; Jen-Hwa Chu; Catherine Askew; A Heather Eliassen; Susan E Hankinson; Peter Kraft; Francine Laden; Rulla M Tamimi
Journal:  Environ Res       Date:  2020-04-15       Impact factor: 6.498

2.  Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting.

Authors:  Peter T Campbell; Christine B Ambrosone; Timothy R Rebbeck; Shuji Ogino; Reiko Nishihara; Hugo J W L Aerts; Melissa Bondy; Nilanjan Chatterjee; Montserrat Garcia-Closas; Marios Giannakis; Jeffrey A Golden; Yujing J Heng; N Sertac Kip; Jill Koshiol; X Shirley Liu; Camila M Lopes-Ramos; Lorelei A Mucci; Jonathan A Nowak; Amanda I Phipps; John Quackenbush; Robert E Schoen; Lynette M Sholl; Rulla M Tamimi; Molin Wang; Matty P Weijenberg; Catherine J Wu; Kana Wu; Song Yao; Kun-Hsing Yu; Xuehong Zhang
Journal:  Cancer Causes Control       Date:  2019-05-08       Impact factor: 2.506

3.  Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications.

Authors:  Gabrielle M Baker; Vanessa C Bret-Mounet; Tengteng Wang; Mitko Veta; Hanqiao Zheng; Laura C Collins; A Heather Eliassen; Rulla M Tamimi; Yujing J Heng
Journal:  J Pathol Inform       Date:  2022-06-28

4.  Prospective study of a diabetes risk reduction diet and the risk of breast cancer.

Authors:  Jae H Kang; Cheng Peng; Jinnie J Rhee; Maryam S Farvid; Walter C Willett; Frank B Hu; Bernard A Rosner; Rulla Tamimi; A Heather Eliassen
Journal:  Am J Clin Nutr       Date:  2020-12-10       Impact factor: 7.045

5.  Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence.

Authors:  Cheng Peng; Yujing J Heng; Donghao Lu; Natalie C DuPre; Kevin H Kensler; Kimberly Glass; Oana A Zeleznik; Peter Kraft; David Feldman; Susan E Hankinson; Kathryn Rexrode; A Heather Eliassen; Rulla M Tamimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-01       Impact factor: 4.254

6.  Early-Life Body Adiposity and the Breast Tumor Transcriptome.

Authors:  Jun Wang; Cheng Peng; Catherine Guranich; Yujing J Heng; Gabrielle M Baker; Christopher A Rubadue; Kimberly Glass; A Heather Eliassen; Rulla M Tamimi; Kornelia Polyak; Susan Hankinson
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 11.816

7.  Low dose environmental radon exposure and breast tumor gene expression.

Authors:  Cheng Peng; Natalie DuPre; Trang VoPham; Yujing J Heng; Gabrielle M Baker; Christopher A Rubadue; Kimberly Glass; Abhijeet Sonawane; Oana Zeleznik; Peter Kraft; Susan E Hankinson; A Heather Eliassen; Jaime E Hart; Francine Laden; Rulla M Tamimi
Journal:  BMC Cancer       Date:  2020-07-28       Impact factor: 4.430

8.  Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors.

Authors:  Helga Bergholtz; Tonje Lien; Frode Lingaas; Therese Sørlie
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-08-06       Impact factor: 2.698

9.  Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm.

Authors:  Mariia V Guryleva; Dmitry D Penzar; Dmitry V Chistyakov; Andrey A Mironov; Alexander V Favorov; Marina G Sergeeva
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

10.  Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer.

Authors:  Max Klebe; Carlo Fremd; Mark Kriegsmann; Katharina Kriegsmann; Thomas Albrecht; Verena Thewes; Martina Kirchner; Pornpimol Charoentong; Nadine Volk; Johannes Haag; Ralph Wirtz; Thordur Oskarsson; Alexandra Schulz; Jörg Heil; Andreas Schneeweiss; Hauke Winter; Peter Sinn
Journal:  JCO Precis Oncol       Date:  2020-07-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.